A new drug promising to help women restore lost libido has been approved by the FDA. But is it just a bill of goods? And does the marketing of this actually hurt the cause of women’s sexual freedom?
The Food and Drug Administration has approved 24 drugs for male sexual dysfunction and zero for women. After rejecting an application for a drug to improve female libido in December, the agency has reconsidered its decision and is giving the manufacturer another chance.
In this week’s Sexual Health Roundup: A new study finds that heterosexual men who are in stable, monogamous relationships keep their distance from a pretty girl if given a sniff of oxytocin (the bonding hormone), a judge is set to rule on Alabama’s policy of segregating HIV-positive prisoners, and researchers in Germany find that social media is more tempting than sex, cigarettes, and alcohol.
You should never feel afraid you have to do anything you do not want to just because someone else wants it from you for themselves, very much including having sex.
One writer calls them “panty-dropping pills” while advocates and feminists have already lined up to fight any sort of FDA approval. Flibanserin is being reported as a “female Viagra” but it’s not lived up to the job of alleviating symptoms of low sexual desire in women. Why?
Sex addiction is a popular topic on talk-shows and in mainstream media (where the goal isn’t accuracy, but ratings), but it isn’t something many sexologists consider credible. I’m not on board with the idea myself.